3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasm Metastasis
5
Lung Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Camurati-Engelmann Syndrome
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Melanoma
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Tertiary Lymphoid Structures
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Interventions
Pemetrexed
39
Cisplatin
33
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Imatinib Mesylate
3
Cerebral Decortication
3
tislelizumab
2
sargramostim
2
fludarabine phosphate
2
defactinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mesothelioma
×
bintrafusp alfa protein, human
×
Clear all
NCT05005429
2025-12-23
BIMES
Fundación GECP
Phase 2
Completed
47 enrolled
9 charts